Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   24/10/2025
149,89 USD (-0,13%)
(-0,13%)   24/10/2025
Grafiek Biogen Inc. Grafiek Biogen Inc.
donderdag 30 oktober 2025, 12:00
Kwartaalcijfers (3de kwartaal)

Biogen Inc. in het nieuws

24 oktober 2025 · Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio · Persbericht

22 oktober 2025 · Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 · Persbericht

14 oktober 2025 · LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025” · Persbericht

14 oktober 2025 · LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" · Persbericht

9 oktober 2025 · Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome · Persbericht

6 oktober 2025 · Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease · Persbericht

6 oktober 2025 · Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease · Persbericht

29 september 2025 · “LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China · Persbericht

24 september 2025 · LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia · Persbericht

23 september 2025 · Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen · Persbericht

Profiel Biogen Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.biogen.com

Hoofdzetel: Cambridge, Massachusetts vlag Verenigde Staten

Mijn selecties